Get the latest news, insights, and market updates on XENE (Xenon Pharmaceuticals Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Xenon Pharmaceuticals: Q3 Earnings Snapshot
BURNABY, British Columbia (AP) — Xenon Pharmaceuticals Inc. XENE) on Monday reported a loss of $90.9 million in its third quarter. On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of $1.15. Nov 3, 2025 - $XENE
Xenon to Report Q3 2025 Financial Results on November 3, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, November 3, 2025. Conference Call/Webcast Information: Oct 27, 2025 - $XENE
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experienceVANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and membe Oct 16, 2025 - $XENE
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum
Xenon Pharmaceuticals (XENE) continues to capture investor attention as its stock posts solid gains over the past month. Shares have risen 9% recently, with the past 3 months delivering a strong 22% return, outpacing many sector peers. See our latest analysis for Xenon Pharmaceuticals. Zooming out, Xenon Pharmaceuticals’ share price strength has picked up steam lately. While its one-year total return remains slightly in the red, its longer-term gains stand out. This combination of recent... Oct 12, 2025 - $XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 77,750 share options. All of the foregoing share options were approved by the Compensation Committee of Oct 7, 2025 - $XENE
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs targeting Kv7 and Nav1.7 as potential non-opioid treatments for pain. Webinar:Developing Novel Non-Opioid Tre Sep 25, 2025 - $XENE
Design Therapeutics Appoints Justin Gover to Board of Directors
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company Sep 10, 2025 - $XENE
Did Higher-Than-Expected Losses Just Shift Xenon Pharmaceuticals' (XENE) Investment Narrative?
Xenon Pharmaceuticals has reported its earnings for the second quarter and first half of 2025, highlighting a net loss of US$84.71 million for the quarter and US$149.75 million for the six months ended June 30, both higher than the same periods last year. The increasing basic loss per share points to rising operational or developmental costs that may be impacting the company's financial performance. We'll explore how these higher-than-expected losses shape Xenon Pharmaceuticals' investment... Aug 24, 2025 - $XENE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple